Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05600127 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

Study acronym: CHASIT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 8, 2023 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4 · Start date changed from estimate of Dec 2022 to Dec 1, 2022 · Secondary endpoints revised (5)v2 Show 3 more changesShow less
    • Study sites: 0 to 4
    • Start date changed from estimate of Dec 2022 to Dec 1, 2022
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with locally advanced or clinically node positive urothelial carcinoma treated with chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.
Trial Details
NCT Number NCT05600127
Lead Sponsor Erasmus Medical Center
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Urothelial Carcinoma
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov